82258 Federal Register / Vol. 89, No. 197 / Thursday, October 10, 2024 / Notices 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

Issued: October 4, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–23402 Filed 10–9–24; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

Notice of Receipt of Complaint; 

Solicitation of Comments Relating to 

the Public Interest 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has received a complaint 

entitled Certain Crafting Machines and 

Components Thereof, DN 3774; the 

Commission is soliciting comments on 

any public interest issues raised by the 

complaint or complainant’s filing 

pursuant to the Commission’s Rules of 

Practice and Procedure. 

FOR FURTHER INFORMATION CONTACT: Lisa 

R. Barton, Secretary to the Commission, 

U.S. International Trade Commission, 

500 E Street SW, Washington, DC 

20436, telephone (202) 205–2000. The 

public version of the complaint can be 

accessed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

For help accessing EDIS, please email 

EDIS3Help@usitc.gov. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server at United 

States International Trade Commission 

(USITC) at https://www.usitc.gov . The 

public record for this investigation may 

be viewed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission has received a complaint 

and a submission pursuant to § 210.8(b) 

of the Commission’s Rules of Practice 

and Procedure filed on behalf of Cricut, 

Inc. on October 4, 2024. The complaint 

alleges violations of section 337 of the 

Tariff Act of 1930 (19 U.S.C. 1337) in 

the importation into the United States, 

the sale for importation, and the sale 

within the United States after 

importation of certain crafting machines 

and components thereof. The complaint 

names as respondents: Hunan Sijiu 

Technology, Co. Ltd. of China; Hunan 

Sijiu Electronic Technology Co., Ltd. of 

China; Guangdong Rongtu Technology 

Co., Ltd. of China; LiPing Zhan of 

China; SainStore Technology Co., Ltd of 

China; Shanghai Sishun E-commerce 

Co., Ltd. of China; Shanghai Sishun Co., 

Ltd. of China; Bozhou Wanxingyu 

Technology Co. Ltd. of China; Bozhou 

Zhongdaxiang Technology Co., Ltd. of 

China; and Wuyi Bohai Electric Tools 

Co., Ltd. of China. The complainant 

requests that the Commission issue a 

limited exclusion order, a general 

exclusion order, cease and desist orders, 

and impose a bond upon respondents’ 

alleged infringing articles during the 60- 

day Presidential review period pursuant 

to 19 U.S.C. 1337(j). 

Proposed respondents, other 

interested parties, members of the 

public, and interested government 

agencies are invited to file comments on 

any public interest issues raised by the 

complaint or § 210.8(b) filing. 

Comments should address whether 

issuance of the relief specifically 

requested by the complainant in this 

investigation would affect the public 

health and welfare in the United States, 

competitive conditions in the United 

States economy, the production of like 

or directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) explain how the articles potentially 

subject to the requested remedial orders 

are used in the United States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the requested remedial 

orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or third 

party suppliers have the capacity to 

replace the volume of articles 

potentially subject to the requested 

exclusion order and/or a cease and 

desist order within a commercially 

reasonable time; and 

(v) explain how the requested 

remedial orders would impact United 

States consumers. 

Written submissions on the public 

interest must be filed no later than by 

close of business, eight calendar days 

after the date of publication of this 

notice in the Federal Register. There 

will be further opportunities for 

comment on the public interest after the 

issuance of any final initial 

determination in this investigation. Any 

written submissions on other issues 

must also be filed by no later than the 

close of business, eight calendar days 

after publication of this notice in the 

Federal Register. Complainant may file 

replies to any written submissions no 

later than three calendar days after the 

date on which any initial submissions 

were due, notwithstanding § 201.14(a) 

of the Commission’s Rules of Practice 

and Procedure. No other submissions 

will be accepted, unless requested by 

the Commission. Any submissions and 

replies filed in response to this Notice 

are limited to five (5) pages in length, 

inclusive of attachments. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. Submissions should refer 

to the docket number (‘‘Docket No. 

3774’’) in a prominent place on the 

cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, Electronic Filing 

Procedures 1). Please note the 

Secretary’s Office will accept only 

electronic filings during this time. 

Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov.) No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. Persons with questions 

regarding filing should contact the 

Secretary at EDIS3Help@usitc.gov. 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) by the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. appendix 3; or (ii) by U.S. 

Government employees and contract 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 197 / Thursday, October 10, 2024 / Notices 82259 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov 

1Effective December 2, 2022, the Medical 

Marijuana and Cannabidiol Research Expansion 

Act, Pub. L. 117–215, 136 Stat. 2257 (2022) 

(Marijuana Research Amendments or MRA), 

amended the Controlled Substances Act (CSA) and 

other statutes. Relevant to this matter, the MRA 

redesignated 21 U.S.C. 823(f), cited in the OSC, as 

21 U.S.C. 823(g)(1). Accordingly, this Decision cites 

to the current designation, 21 U.S.C. 823(g)(1), and 

to the MRA-amended CSA throughout. 

2Prior Agency decisions have addressed whether 

it is appropriate to consider a provision of 21 U.S.C. 

824(a) when determining whether to grant a 

practitioner registration application. For over fortyfive years, Agency decisions have concluded that it 

is. Robert Wayne Locklear, M.D., 86 FR 33738, 

33744–45 (2021) (collecting cases); see also Dinorah 

Drug Store, Inc., 61 FR 15972, 15973–74 (1996). 

3Based on the Government’s submissions in its 

RFAA dated July 3, 2023, the Agency finds that 

service of the OSC on Applicant was adequate. 

Specifically, the included Declaration of a DEA 

Diversion Investigator indicates that on January 30, 

2023, Applicant was personally served with the 

OSC. RFAAX 1, at 2. 

4Within the document where Applicant 

withdrew his request for hearing, Applicant’s 

counsel indicated that Applicant would ‘‘continue 

with the Corrective Action Plan route that was 

parallel to the litigation path, but unrelated to the 

hearing.’’ Id. at 1. 

5See also 21 CFR 1301.43(f)(3) (‘‘A party held to 

be in default may move to set aside a default final 

order issued by the Administrator by filing a motion 

no later than 30 days from the day of issuance by 

the Administrator of a default final order. Any such 

motion shall be granted only upon a showing of 

good cause to excuse the default.’’) Any motion to 

set aside a default and any response shall be filed 

and served by email to the other party and to Office 

of the Administrator, Drug Enforcement 

Administration at dea.addo.attorneys@dea.gov. 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: October 7, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–23444 Filed 10–9–24; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Salman Akbar, M.D.; Decision and 

Order 

On January 27, 2023, the Drug 

Enforcement Administration (DEA or 

Government) issued an Order to Show 

Cause (OSC) to Salman Akbar, M.D., of 

Richmond, Virginia (Applicant). 

Request for Final Agency Action 

(RFAA), Exhibit (RFAAX) 1, Attachment 

E, at 1, 4. The OSC proposed the denial 

of Applicant’s application for a DEA 

Certificate of Registration (registration), 

Control No. W22109452C, alleging that 

Applicant has committed acts that 

would render his registration 

inconsistent with the public interest. Id. 

at 1, 2 (citing 21 U.S.C. 823(g)(1),1

824(a)(4) 2). 

The OSC notified Applicant of his 

right to file with DEA a written request 

for hearing, and that if he failed to file 

such a request, he would be deemed to 

have waived his right to a hearing and 

be in default. Id. at 2 (citing 21 CFR 

1301.43). Here, Applicant filed a timely 

answer and request for hearing on 

February 28, 2023,3 but ultimately 

withdrew his request for hearing on 

March 27, 2023. See RFAAX 1, 

Attachment F.4 On March 27, 2023, 

Chief Administrative Law Judge John J. 

Mulrooney, II, (the Chief ALJ) issued a 

Termination Order that terminated the 

proceedings. 21 CFR 1301.43(c) 

provides that, ‘‘[i]n the event . . . a 

person who has requested a hearing fails 

to plead . . . or otherwise defend, said 

party shall be deemed to be in default 

. . . .’’ By voluntarily withdrawing his 

hearing request, Respondent ‘‘fail[ed] to 

. . . otherwise defend.’’ 21 CFR 

1301.43(c). Accordingly, Respondent is 

‘‘deemed to be in default.’’ Id.; Default 

Provisions for Hearing Proceedings 

Relating to the Revocation, Suspension, 

or Denial of a Registration, 87 FR 68036 

(Nov. 14, 2022).5 See RFAAX 1, 

Attachment G. ‘‘A default, unless 

excused, shall be deemed to constitute 

a waiver of the registrant’s/applicant’s 

right to a hearing and an admission of 

the factual allegations of the [OSC].’’ 21 

CFR 1301.43(e). 

Further, ‘‘[i]n the event that a 

[registrant/applicant] . . . is deemed to 

be in default . . . DEA may then file a 

request for final agency action with the 

Administrator, along with a record to 

support its request. In such 

circumstances, the Administrator may 

enter a default final order pursuant to 

[21 CFR] § 1316.67.’’ Id. § 1301.43(f)(1). 

Here, the Government has requested 

final agency action based on Applicant’s 

default pursuant to 21 CFR 1301.43(c), 

(d), 1301.46. RFAA, at 1; see also 21 

CFR 1316.67. 

I. Findings of Fact 

The Agency finds that, in light of 

Applicant’s default, the factual 

allegations in the OSC are admitted. 

Applicant is deemed to have admitted 

that on March 2, 2020, DEA issued 

Applicant an Immediate Suspension 

Order and Order to Show Cause that 

suspended Applicant’s previous DEA 

registration, Control No. BA5092856, 

and immediately rendered Applicant 

without authority to issue prescriptions 

for controlled substances. RFAAX 1, 

Attachment E, at 1–2; see also RFAAX 

1, Attachment B. Further, on October 

20, 2021, by Order of the then-Acting 

Administrator, Applicant’s DEA 

registration, Control No. BA5092856, 

was revoked. RFAAX 1, Attachment E, 

at 2; see also RFAAX 1, Attachment C. 

Nonetheless, Applicant is deemed to 

have admitted, and the Agency finds, 

that between on or about January 15, 

2021, and on or about January 6, 2022, 

Applicant issued at least 17 

prescriptions for controlled substances, 

including four prescriptions for 

oxycodone (a Schedule II controlled 

substance), two prescriptions for 

hydrocodone (a Schedule II controlled 

substance), five prescriptions for 

lorazepam (a Schedule IV controlled 

substance), two prescriptions for 

zolpidem (a Schedule IV controlled 

substance), one prescription for 

clonazepam (a Schedule IV controlled 

substance), two prescriptions for 

pregabalin (a Schedule V controlled 

substance), and one prescription for 

diazepam (a Schedule IV controlled 

substance). RFAAX 1, Attachment E, at 

2; see also RFAAX 1, Attachment D. 

Applicant is deemed to have admitted, 

and the Agency finds, that each of these 

17 prescriptions was issued without a 

DEA registration and outside the usual 

course of professional practice. Id. 

II. Discussion 

A. The Five Public Interest Factors 

Pursuant to section 303(g)(1) of the 

CSA, ‘‘[t]he Attorney General shall 

register practitioners . . . to dispense 

. . . controlled substances . . . if the 

applicant is authorized to dispense . . . 

controlled substances under the laws of 

the State in which he practices.’’ 21 

U.S.C. 823(g)(1). Section 303(g)(1) 

further provides that an application for 

a practitioner’s registration may be 

denied upon a determination that ‘‘the 

issuance of such registration . . . would 

be inconsistent with the public 

interest.’’ Id. In making the public 

interest determination, the CSA requires 

consideration of the following factors: 

(A) The recommendation of the 

appropriate State licensing board or 

professional disciplinary authority. 

(B) The applicant’s experience in 

dispensing, or conducting research with 

respect to controlled substances. 

(C) The applicant’s conviction record 

under Federal or State laws relating to the 


lotter on DSK11XQN23PROD with NOTICES1